Loading
Life sciences · Journal article
International Journal of Innovative Technologies in Social Science · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have evolved from glucose-lowering agents for type 2 diabetes (T2D) into multifunctional therapies with effects extending across multiple metabolic and organ systems. This review summarizes current evidence regarding the pleiotropic effects, safety profile, and future therapeutic potential of GLP-1–based therapies beyond diabetes and obesity. Clinical evidence indicates that GLP-1RAs, particularly semaglutide, may reduce cardiovascular events and slow kidney disease progression, while also improving outcomes in heart failure with preserved ejection fraction. Beneficial effects have additionally been reported in metabolic dysfunction-associated steatohepatitis, osteoarthritis, obstructive sleep apnea, and peripheral artery disease. Emerging evidence suggests potential neuroprotective effects, although the role of GLP-1–based therapies in neurodegenerative diseases remains under investigation. Despite their generally favorable safety profile, gastrointestinal adverse events are common, while pancreatic, biliary, renal, ophthalmic, and other less frequent complications require appropriate clinical monitoring. The development of dual and triple receptor agonists, including tirzepatide, retatrutide, CagriSema, and amycretin, may further enhance weight loss and metabolic efficacy. Future treatment strategies may increasingly incorporate personalized selection of receptor profiles based on metabolic phenotype, comorbidities, therapeutic goals, and individual tolerability. Overall, GLP-1–based therapies represent an expanding therapeutic platform with potential applications extending well beyond glycemic control and weight management, although long-term clinical trials are required to establish their efficacy, safety, and organ-protective effects across broader patient populations.